Cited by 9Dementia and Cognitive Impairment ResearchArtificial Intelligence in HealthcareMachine Learning in Healthcare

XGBoost for Interpretable Alzheimer’s Decision Support

Open access
Kadem, Mason, Noseworthy, Michael, Doyle, Thomas·2023·Proceedings of the AAAI Symposium Series

Abstract

Despite their necessity in directing patient care worldwide, simple and accurate diagnostic tools for early Alzheimer’s disease (AD) do not exist. To support healthcare decision-making and planning, this research leverages large, multi-site accessible data and state-of-the-art supervised machine learning (XGBoost) to enable rapid, accurate, low-cost, accessible, non-invasive, interpretable, and early clinical evaluation of AD. Machine learning was employed to combine three key features: Everyday Cognition Questionnaire, Alzheimers Disease Assessment Scale, and Delayed Total Recall, achieving area under the receiver operating characteristic curves scores consistently above 97%. The selected features are important because they are non-invasive and easily collected. Low performance on delayed recall alone appears to distinguish most AD patients, consistent with the pathophysiology of AD where individuals having problems storing new information into long-term memory. Distinguishing this research from existing literature was the focus of enhancing the model's interpretability while maintaining performance of more complex and opaque models. The interpretable model enables understanding of the decision process, vital for clinical adoption of machine learning tools in AD evaluation. In summary, we present a methodology which identified accessible and noninvasive features, each with their absolute thresholds, together with a clinically operable decision route, to accurately and rapidly detect, differentiate, and diagnose Alzheimer's disease patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1609/aaaiss.v1i1.27491

Cites

0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The distinction between explainability and interpretability is crucial for designing effective clinical AI agents.

    “The distinction between explainability and interpretability is crucial for designing effective clinical AI agents.”

    From Human-Clinical AI Agent Collaboration (2025) · cites this paper as Kadem, Noseworthy, and Doyle 2023

  • Explainability and interpretability represent fundamentally different approaches to AI transparency that impact decision support in healthcare.

    “While these terms are often used interchangeably, they represent fundamentally different approaches to AI transparency that impact decision support in healthcare (Kadem, Noseworthy, and Doyle 2023; Kadem 2023).”

    From Human-Clinical AI Agent Collaboration (2025) · cites this paper as Kadem, Noseworthy, and Doyle 2023

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 19

  1. Borisov, V.; Leemann, T.; Seßler, K.; Haug, J.; Pawelczyk, M.; and Kasneci, G. 2022. Deep Neural Networks and Tab- ular Data: A Survey. IEEE Trans. Neural Networks Learn. Syst., 1-21.
  2. Breiman, L. 2001. Statistical Modeling: The Two Cultures (with comments and a rejoinder by the author). Statistical Science, 16(3): 199-231. Publisher: Institute of Mathemati- cal Statistics.
  3. Chen, T.; and Guestrin, C. 2016. XGBoost: A Scalable Tree Boosting System. In KDD '16: Proceedings of the 22nd ACM SIGKDD International Conference on Knowl- edge Discovery and Data Mining, 785-794. New York, NY, USA: Association for Computing Machinery. ISBN 978-1- 45034232-2.
  4. Guarino, A.; Favieri, F.; Boncompagni, I.; Agostini, F.; Can- tone, M.; and Casagrande, M. 2019. Executive Functions in Alzheimer Disease: A Systematic Review. Frontiers in Ag- ing Neuroscience, 10: 437.
  5. Hall, P.; and Gill, N. 2019. An introduction to machine learning interpretability. O'Reilly Media, Incorporated.
  6. Kadem, M. 2023. Interpretable Machine Learning in Alzheimer's Disease Dementia. Master's thesis, McMaster University.
  7. Lindbergh, C. A.; Walker, N.; La Joie, R.; Weiner-Light, S.; Staffaroni, A. M.; Casaletto, K. B.; Elahi, F.; Walters, S. M.; You, M.; Cotter, D.; Asken, B.; Apple, A. C.; Tsoy, E.; Neuhaus, J.; Fonseca, C.; Wolf, A.; Cobigo, Y.; Rosen, H.; Kramer, J. H.; and Network, H. A. 2021. Worth the Wait: Delayed Recall after 1 Week Predicts Cognitive and Medial Temporal Lobe Trajectories in Older Adults. J. Int. Neu- ropsychol. Soc., 27(4): 382-388.
  8. Lundberg, S. M.; Erion, G.; Chen, H.; DeGrave, A.; Prutkin, J. M.; Nair, B.; Katz, R.; Himmelfarb, J.; Bansal, N.; and Lee, S.-I. 2020. From local explanations to global under- standing with explainable AI for trees. Nat. Mach. Intell., 2(1): 56-67.
  9. Lyketsos, C. G.; Lopez, O.; Jones, B.; Fitzpatrick, A. L.; Breitner, J.; and DeKosky, S. 2002. Prevalence of neuropsy- chiatric symptoms in dementia and mild cognitive impair- ment: results from the cardiovascular health study. JAMA, 288(12): 1475-1483.
  10. Mattsson, N.; Palmqvist, S.; Stomrud, E.; Vogel, J.; and Hansson, O. 2019. Stagingβ-Amyloid Pathology With Amyloid Positron Emission Tomography. JAMA Neurology, 76(11): 1319-1329.
  11. Palmqvist, S.; Tideman, P.; Cullen, N.; Zetterberg, H.; Blennow, K.; Dage, J. L.; Stomrud, E.; Janelidze, S.; Mattsson-Carlgren, N.; and Hansson, O. 2021. Predic- tion of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Na- ture Medicine, 27(6): 1034-1042. Number: 6 Publisher: Na- ture Publishing Group.
  12. Palmqvist, S.; Zetterberg, H.; Blennow, K.; Vestberg, S.; An- dreasson, U.; Brooks, D. J.; Owenius, R.; Hägerström, D.; Wollmer, P.; Minthon, L.; and Hansson, O. 2014. Accu- racy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA neu- rology, 71(10): 1282-1289.
  13. Rabinovici, G. D.; Gatsonis, C.; Apgar, C.; Chaudhary, K.; Gareen, I.; Hanna, L.; Hendrix, J.; Hillner, B. E.; Olson, C.; Lesman-Segev, O. H.; Romanoff, J.; Siegel, B. A.; Whitmer, R. A.; and Carrillo, M. C. 2019. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA, 321(13): 1286-1294.
  14. Rudin, C. 2019. Stop explaining black box machine learn- ing models for high stakes decisions and use interpretable models instead. Nat. Mach. Intell., 1(5): 206-215.
  15. Tang, L.; Wu, X.; Liu, H.; Wu, F.; Song, R.; Zhang, W.; Guo, D.; Feng, J.; and Li, C. 2021. Individualized Prediction of Early Alzheimer's Disease Based on Magnetic Resonance Imaging Radiomics, Clinical, and Laboratory Examinations: A 60-Month Follow-Up Study. Journal of magnetic reso- nance imaging: JMRI, 54(5): 1647-1657.
  16. van de Schoot, R.; de Bruin, J.; Schram, R.; Zahedi, P.; de Boer, J.; Weijdema, F.; Kramer, B.; Huijts, M.; Hooger- werf, M.; Ferdinands, G.; Harkema, A.; Willemsen, J.; Ma, Y.; Fang, Q.; Hindriks, S.; Tummers, L.; and Oberski, D. L. 2021. An open source machine learning framework for ef- ficient and transparent systematic reviews. 3(2): 125-133. Number: 2 Publisher: Nature Publishing Group.
  17. van der Flier, W. M.; de Vugt, M. E.; Smets, E. M. A.; Blom, M.; and Teunissen, C. E. 2023. Towards a future where Alzheimer's disease pathology is stopped before the onset of dementia. Nat. Aging, 3(5): 494-505.
  18. Yamazaki, Y.; Zhao, N.; Caulfield, T. R.; Liu, C.-C.; and Bu, G. 2019. Apolipoprotein E and Alzheimer disease: pathobi- ology and targeting strategies. Nature Reviews Neurology, 15(9): 501-518. Number: 9 Publisher: Nature Publishing Group.
  19. Yan, L.; Zhang, H.-T.; Goncalves, J.; Xiao, Y.; Wang, M.; Guo, Y.; Sun, C.; Tang, X.; Jing, L.; Zhang, M.; Huang, X.; Xiao, Y.; Cao, H.; Chen, Y.; Ren, T.; Wang, F.; Xiao, Y.; Huang, S.; Tan, X.; Huang, N.; Jiao, B.; Cheng, C.; Zhang, Y.; Luo, A.; Mombaerts, L.; Jin, J.; Cao, Z.; Li, S.; Xu, H.; and Yuan, Y. 2020. An interpretable mortality prediction model for COVID-19 patients. Nat. Mach. Intell., 2(5): 283- 288.

Cited by

Sorted by citations

Authors
Kadem, M., Noseworthy, M., & Doyle, T.
Affiliations
  • Population Health Research Institute (CA)
  • McMaster University (CA)
  • Vector Institute (CA)
Venue
Proceedings of the AAAI Symposium Series
Published
2023-10-03
Volume
1
Issue
1
Pages
135-141
ISSN
2994-4317 (ISSN-L)
OpenAlex
W4388521771
Cited by
2
References
23
Citations by year
2025: 1 · 2024: 1
FWCI
1.18
Type
conference paper
Language
en
Open access
Locations
Proceedings of the AAAI Symposium Series (publishedVersion)
Funders
  • U.S. Department of Defense (U01 AG024904, W81XWH, W81XWH-12-2-, W81XWH1220012, AG024904)
  • Alzheimer's Association (U01 AG024904, W81XWH-12-2-0012)
  • Bristol-Myers Squibb (U01 AG024904, AG024904, W81XWH-12-2-0012)
  • Eli Lilly and Company (U01 AG024904, AG024904, W81XWH-12-2-0012)
  • Pfizer (AG024904, W81XWH-12-2-0012, U01 AG024904)
  • Biogen (W81XWH-12-2-0012, U01 AG024904, AG024904)
  • University of Southern California (W81XWH-12-2-0012, U01 AG024904)
  • F. Hoffmann-La Roche (W81XWH-12-2-0012, AG024904, U01 AG024904)
  • Meso Scale Diagnostics (U01 AG024904, AG024904, W81XWH-12-2-0012)
  • Alzheimer's Disease Neuroimaging Initiative (W81XWH-12-2–0012, U01AG024904, AG024904, W81XWH-12-2-)
  • BioClinica (U01 AG024904, W81XWH-12-2-0012, AG024904)
  • Novartis Pharmaceuticals Corporation (W81XWH-12-2-0012, U01 AG024904, AG024904)
  • Northern California Institute for Research and Education (U01 AG024904, W81XWH-12-2-0012)
  • Eisai (W81XWH-12-2-0012, U01 AG024904, AG024904)
  • Servier (AG024904, W81XWH-12-2-0012, U01 AG024904)
  • H. Lundbeck A/S (U01 AG024904, AG024904, W81XWH-12-2-0012)
  • IXICO (AG024904, W81XWH-12-2-0012, U01 AG024904)
  • Ministère de la Défense Nationale
  • National Institutes of Health (3u01ag024904-10s2, W81XWH, W81XWH-12-2-0012, U01-AG024904, AG024904)
  • Genentech (W81XWH-12-2-0012, AG024904, U01 AG024904)
  • Canadian Institutes of Health Research (U01 AG024904, W81XWH-12-2-0012)
  • Natural Sciences and Engineering Research Council of Canada
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Health Professions › Health Information Management › Artificial Intelligence in Healthcare
  • Physical Sciences › Computer Science › Artificial Intelligence › Machine Learning in Healthcare
Keywords
Alzheimer's disease, early diagnosis, XGBoost, model interpretability, clinical decision support, Alzheimer's Disease Assessment Scale, delayed recall

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review